Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus

Internal Medicine

Volumn 52, Issue 10, 2013, Pages 1029-1034

  Suzuki, Daisuke ^a   Toyoda, Masao ^a   Kimura, Moritugu ^a   Miyauchi, Masaaki ^a   Yamamoto, Naoyuki ^a   Sato, Hiroki ^a   Tanaka, Eitaro ^a   Kuriyama, Yusuke ^a   Miyatake, Han ^a   Abe, Makiko ^a   Umezono, Tomoya ^a   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BMI; Human GLP 1 analogue; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C PEPTIDE; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PENTRAXIN 3; PIOGLITAZONE; PROINSULIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY FAT; BODY MASS; BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSITY; AGED; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FASTING; FATTY LIVER; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTRA-ABDOMINAL FAT; JAPAN; KIDNEY; LIVER; MALE; MIDDLE AGED; PROINSULIN; SERUM AMYLOID P-COMPONENT; SUBCUTANEOUS FAT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84877841678     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8961     Document Type: Article

References (22)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998.
2. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53: 1925-1932, 2009.
3. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66 (Suppl 1): S37-S43, 2004.
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006.
5. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43: 1664-1669, 2000.
6. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84-90, 2009.
7. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473-481, 2009.
8. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32: 1224-1230, 2009.
9. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52: 2046-2055, 2009.
10. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26: 1013-1022, 2010.
11. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K. Basal and dynamic proinsulin-insulin relationship to assess β-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 285: E155-E162, 2003.
12. Okauchi Y, Kishida K, Funahashi T, et al. Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middle-aged general population. Diabetes Care 32: e122, 2009.
13. Inoue K, Kodama T, Daida H. Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med 2012: 657025, 2012.
14. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 66: 987-992, 2002.
15. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 31: 2472-2488, 2009.
16. Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun 330: 577-584, 2005.
17. Jendle J, Nauck MA, Matthews DR, et al; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 11: 1163-1172, 2009.
18. Kim Chung le T, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 390: 613-618, 2009.
19. Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal 2012: 496453, 2012.
20. Li L, Miao Z, Liu R, Yang M, Liu H, Yang G. Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 17: 1168-1178, 2011.
21. Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 666: 251-256, 2011.
22. Osorio-Conles O, Guitart M, Chacón MR, et al. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. Am J Physiol Endocrinol Metab 301: E1254-E1261, 2011.